The Icahn School of Medicine at Mount Sinai (ISMMS) appointed Joel Dudley, Ph.D., as the first director of its Institute for Next Generation Healthcare. Dennis S. Charney, M.D., Anne and Joel Ehrenkranz Dean, ISMMS, and president for academic affairs, Mount Sinai Health System, explained that the institute is a new venture that will “assure Mount Sinai’s position as an internationally recognized hub for research, clinical care, and education in the burgeoning and highly competitive field of digital medicine.”

The Institute is setting out to build a new model of research, innovation, and market delivery to hasten and help shape the impending revolution in health care, continued Dr. Charney, adding that its vision is to harness cutting-edge science, technology, analytics, and human-centered design to enhance the health and vitality of people everywhere.

“Dr. Dudley will help lay a foundation for research and technology development programs that will accelerate the transition to next-generation health care and transform medicine in the coming decades,” he noted.

Dr. Dudley, who specializes in translational bioinformatics and precision medicine, is an associate professor of genetics and genomic sciences, as well as director of the Harris Center for Precision Wellness and Director of the Center for Biomedical Informatics. He has authored or co-authored more than 85 scientific papers and co-authored the first textbook on personalized genomics. Dr. Dudley is named on patents in clinical genomics, serves as an advisor to startups, and has experience launching venture-backed start-up companies. He was included among the 100 Most Creative People of the Year for 2014 by Fast Company magazine.

“Our vision is to realize exponential improvements in patient outcomes and to improve the care experience for both providers and patients through human-centered application of advanced technologies,” said Dr. Dudley. “We also aim to accelerate research discovery using more intelligent, agile, and democratized research models. Participants in our clinical trials engage with our scientists and data analysts in a dynamic feedback loop, allowing for real-time exploration and the advancement of knowledge and practice. Our approach reduces the gap between what we know and what we do in a way that accelerates progress in human health and well-being globally.“

Previous articleBest Presidential Candidate for Life Science Research
Next articleA New Era Predicted for LC-MS in the Clinical Lab